Related Experiment Video
Updated: Jan 21, 2026

Echocardiographic Characterization of Left Ventricular Structure, Function, and Coronary Flow in Neonate Mice
Published on: April 7, 2022
Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery
Sean van Diepen1, Rajendra H Mehta2, Jeffrey D Leimberger2
1Division of Cardiology, Departments of Critical Care and Medicine, University of Alberta, Edmonton, Alberta, Canada; Canadian VIGOUR Center, University of Alberta, Edmonton, Alberta, Canada.
Levosimendan reduced 90-day mortality and low cardiac output syndrome (LCOS) in patients undergoing isolated coronary artery bypass grafting (CABG). However, no benefits were observed in valve or combined surgeries, indicating procedure-specific effects for levosimendan.
Area of Science:
- Cardiology
- Cardiovascular Surgery
- Pharmacology
Background:
- Levosimendan has shown benefits in specific cardiac surgery populations.
- The LEVO-CTS trial found no overall difference in outcomes with levosimendan versus placebo in a broad cardiac surgery group.
- Previous studies suggested levosimendan's efficacy in isolated coronary artery bypass grafting (CABG).
Purpose of the Study:
- To analyze treatment outcomes and costs of levosimendan versus placebo across different cardiac surgical procedures.
- To investigate whether levosimendan's benefits are specific to certain surgical types, particularly isolated CABG.
- To evaluate the impact of levosimendan on mortality, renal function, myocardial infarction, circulatory support, and costs in subgroups.
Main Methods:
- A prespecified subgroup analysis of the LEVO-CTS trial was conducted.
- Patients were categorized into isolated CABG, isolated valve, or combined CABG/valve surgery groups.
- Outcomes included composite endpoints (mortality, renal replacement, MI, circulatory support), 90-day mortality, low cardiac output syndrome (LCOS), and 30-day costs.
Main Results:
- Levosimendan demonstrated a significant reduction in 90-day mortality (2.1% vs 7.9%) and LCOS (12.0% vs 22.1%) in the isolated CABG group.
- No significant differences in composite outcomes or 90-day mortality were observed for levosimendan in isolated valve or combined procedures.
- Thirty-day medical costs, excluding study drug, showed no significant difference between levosimendan and placebo groups across all procedures.
Conclusions:
- Levosimendan is associated with improved outcomes, specifically lower 90-day mortality and LCOS, in patients undergoing isolated CABG.
- The drug did not show significant benefits in patients undergoing isolated valve or combined CABG/valve surgery.
- These findings highlight the procedure-specific efficacy of levosimendan in cardiac surgery patients.
More Related Videos
13:10Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA
Published on: April 24, 2017
06:34Evaluation of Left Ventricular Structure and Function using 3D Echocardiography
Published on: October 28, 2020
Related Concept Videos
Reduced Mass Coordinates: Isolated Two-body Problem
Heart Valves
The AV valves prevent the backflow of blood from the ventricles to the atria during ventricular contraction. These valves function with the assistance of the chordae tendineae and papillary muscles. When the ventricles are relaxed, the chordae tendineae are slack, allowing blood to flow from the atria into the...
Coronary Circulation
Coronary circulation begins at the base of the aorta, where two main arteries arise—the left and right coronary arteries. These arteries encircle the heart in the coronary sulcus and supply the...
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Functional Groups
Methods of reducing fever
Pharmacological Methods of Reducing Fever: